Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723710 | 0.86 | MAP3K12 (0.35) | MAP3K12 | |
| SCHEMBL20932927 | 0.86 | MAP3K12 (0.44) | GRNSORT1KDM4EMAP3K12MAPK14 | |
| SCHEMBL12859127 | 0.86 | MAP3K12 (0.38) | KDM4EMAP3K12 | |
| SCHEMBL15723703 | 0.86 | MAP3K12 (0.38) | GRNSORT1KDM4EMAP3K12MAPK14 | |
| SCHEMBL20047815 | 0.82 | MAPK14 (0.31) | GRNSORT1KDM4EMAPK14 | |
| SCHEMBL23546913 | 0.79 | MAP3K12 (0.32) | KDM4EMAP3K12GAA | |
| SCHEMBL12859123 | 0.79 | MEN1 (0.34) | KDM4EMAP3K12POLB | |
| SCHEMBL13487955 | 0.79 | KDM4E (0.36) | GRNSORT1KDM4EMAPK14GAA | |
| SCHEMBL2765515 | 0.79 | KDM4E (0.33) | GRNSORT1KDM4E | |
| SCHEMBL23403293 | 0.78 | GRN (0.38) | GRNSORT1KDM4EMAPK14GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | ZENO MANAGEMENT, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9403815-B2 | Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | GRN 3131/4885SORT1 3722/4885KDM4E 4232/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | GRN 3131/4885SORT1 3722/4885KDM4E 4232/4885 |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | FXR1, SLC10A1, NR1H4 | GRN 4104/4885SORT1 3816/4885KDM4E 4194/4885 |
| US-20230192720-A1 | MACROCYCLIC COMPOUNDS | MCL1, BCL2A1, BCL2L1 | GRN 252/4885SORT1 4429/4885KDM4E 2397/4885 |
| US-20130165416-A1 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS | IAPP, APP, BACE1 | GRN 36/4885SORT1 188/4885KDM4E 4398/4885 |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | GRN 3131/4885SORT1 3722/4885KDM4E 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.